SCHEMBL25752642

SCHEMBL25752642

Cn1cc(NC(=O)OC(C)(C)C)c2c(=O)n(C3CCC3)ccc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 3/20 0.39
OPRD1 P41143 3/20 0.39
OGFRL1 Q5TC84 3/20 0.39
KMT2A Q03164 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
PRKCG P05129 1/20 0.35
PRKCB P05771 1/20 0.35
PRKCA P17252 1/20 0.35
PRKCH P24723 1/20 0.35
PRKCE Q02156 1/20 0.35
PRKCD Q05655 1/20 0.35
PIM1 P11309 1/20 0.34
MARK3 P27448 1/20 0.34
MAP4K2 Q12851 1/20 0.34
CAMK2B Q13554 1/20 0.34
PIM3 Q86V86 1/20 0.34
PIM2 Q9P1W9 1/20 0.34
TP53 P04637 3/20 0.34
GRM1 Q13255 1/20 0.34
CNR2 P34972 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25752562 0.96 OPRM1 (0.36) OPRM1OPRD1OGFRL1KMT2AL3MBTL1
SCHEMBL30895158 0.87 P2RX7 (0.35) OPRM1OPRD1OGFRL1
SCHEMBL30895094 0.87 P2RX7 (0.35) OPRM1OPRD1OGFRL1
SCHEMBL27199346 0.84 ALDH1A1 (0.38) KMT2ATP53GRM1RXFP1ALDH1A1
SCHEMBL25670291 0.83 CNR2 (0.39) CNR2RXFP1ABL1KDM4E
SCHEMBL30895101 0.80 DRD2 (0.38) OPRM1OPRD1OGFRL1CNR2
SCHEMBL27199323 0.79 ALDH1A1 (0.34) KMT2ATP53GRM1RXFP1ALDH1A1
SCHEMBL21246072 0.78 OPRM1 (0.45) OPRM1OPRD1OGFRL1KMT2AL3MBTL1
SCHEMBL25750429 0.78 ELANE (0.38) CNR2ABL1
SCHEMBL25670769 0.78 CNR2 (0.42) CNR2RXFP1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 US disclosed
CN-118401516-A TYK2 inhibitors, compositions and methods thereof 凌科药业(杭州)有限公司 2024-07-26 CN disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 US disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 OPRM1 4435/4885OPRD1 4532/4885OGFRL1 3005/4885
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 OPRM1 4435/4885OPRD1 4532/4885OGFRL1 3005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.